The Lab Imperative: R&D Real Estate in Life Sciences
Authors
Kamya Miglani
Kaiwen Li
Key highlights
- R&D labs top the expansion plans of APAC life sciences organizations: R&D labs account for 24% of the average APAC life sciences corporate real estate (CRE) portfolio, and 80% of organizations plan to expand that space over the next three to five years, the highest expansion intent of any asset type.
- R&D labs bring operational demands that stretch facilities teams: Complex biosafety requirements, a scarcity of technical talent and rising operating costs make R&D labs among the most sophisticated spaces to manage in a CRE portfolio.
- Future-fit R&D labs are accessed, equipped and powered differently: Flexible lab models, automation-ready specifications and sustainability-led design are reshaping how organizations plan and operate R&D lab space.
R&D lab demand in Asia Pacific is rising
Asia Pacific is becoming a center of gravity for pharmaceutical and biotechnology innovation. APAC first pulled level with the U.S. in biopharma patent filings in 2023 and has held the lead every year since, according to the WIPO IP Statistics Data Center. The gap widened in 2025 as U.S. patent filings declined.
This growth is broad-based rather than concentrated in a single field. APAC's pharmaceutical patent filings have grown 156% since 2010, while biotechnology patent filings have grown faster still, at 229%. While patent filings measure innovation output and not space demand, but they show where R&D activity is concentrating.
Licensing activity points the same way. Spurred by a wave of patent expiries, global biopharma companies are refilling their pipelines by licensing assets from innovative Chinese biotechnology organizations, and China is now home to around 40% of global out-licensing deal value. In the short term, this is fueling demand for high-specification wet labs, R&D facilities and advanced manufacturing space within China's major hubs.
These changes are increasingly reflected in real estate strategy. JLL's Future of Work Survey 2026, which surveyed 91 life sciences CRE leaders across APAC, found that R&D lab space accounts for 24% of the average life sciences CRE portfolio in the region, and that 80% of organizations plan to expand their R&D lab space over the next three to five years, the highest expansion intent of any asset type surveyed in this sector.
This intent of expansion of R&D space showcases the strategic core of how life sciences companies think about their real estate. Organizations are preparing to commit substantial capital to an asset type that is operationally complex, expensive to fit out and difficult to reconfigure once built. Getting the operating model right from the outset is therefore critical, as mistakes made during lab setup are costly to unwind.
What makes an R&D lab’s operational demands so distinct?
Most R&D labs in life sciences are wet labs, where scientists work hands-on with liquids, chemicals and biological materials. Handling these materials safely requires specialized building infrastructure, including dedicated ventilation, plumbing and waste handling systems. R&D labs also serve a broad range of users, spanning academic, institutional and corporate research settings.
Complex Biosafety Requirements
R&D labs handle biological agents ranging from benign lab strains to organisms capable of causing fatal disease. The U.S. Centers for Disease Control and Prevention (CDC) and National Institutes of Health (NIH) classify these into four biosafety levels (BSL). BSL-1 covers well-characterized agents not known to cause disease, while BSL-2 covers agents associated with human disease that pose moderate hazards. BSL-3 applies to agents that may cause serious or potentially lethal disease through inhalation, and BSL-4 is reserved for dangerous and exotic agents that carry a high risk of life-threatening disease.
Each step up in biosafety level raises the consequences of a containment failure, which can put researchers, the surrounding community and the continuity of research at risk. As a result, R&D lab design is dictated by biocontainment requirements rather than general workplace standards. Biosafety is therefore a primary driver of how lab space is designed, operated and maintained.
Tighter lab regulation and pressure to prove value
The complex technical demands shape how APAC life sciences CRE leaders see the next three to five years, and JLL's Future of Work Survey 2026 shows them under pressure from two angles. The first is regulation: 38% rank regulatory and compliance complexity among the top constraints on CRE's ability to create value, well above the APAC average of 29%. The second is the pressure to evolve. 34% struggle to report the right metrics to demonstrate CRE's business value, compared with 25% across APAC. Life sciences CRE teams are expected to keep highly regulated lab space compliant while modernizing how they operate and how they prove their value.
Technical Facilities Management (FM) requirements
Complex biosafety requirements also place considerable demands on FM teams. According to JLL's Global State of Facilities Management Report 2025, 54% of global life sciences FM leaders cite a scarcity of candidates with the required technical skills or licenses as a top talent challenge, and 85% rank succession planning and knowledge transfer as their top workforce priority.
Much of this specialist work is contracted out: around three in four FM job openings in life sciences are posted by third-party service providers rather than in-house teams, according to JLL Research analysis of Draup job-posting data.
Cost pressure compounds the talent challenge. 92% of global life sciences FM leaders cite budget constraints and escalating operational costs as their top FM-related concern, compared with 84% across industry sectors. Technology adoption, meanwhile, remains at an early stage. Only 5% of APAC life sciences CRE leaders report widely deploying AI throughout CRE operations across their portfolio, compared with 15% across all industries in the region, while 7 in 10 life sciences organizations in APAC are still researching or piloting.
Future-fit R&D labs
As demand for R&D lab space grows, organizations are rethinking how they secure, specify and operate it. Three shifts stand out.
Accessed: flexible routes to lab space
Rather than committing to long lead times and heavy upfront capital expenditure, life sciences organizations are increasingly turning to flexible lab operators to access R&D-ready space faster. APAC offers three main routes to R&D lab space without ownership, each serving a different tenant base. Space formats range from individual benches to private suites, depending on tenant scale and operating model.
- Private operators such as Life Science Incubator (LSI) and NSG BioLabs in Singapore and BioLabs Tokyo lease space on the open market to tenants ranging from startups to multinationals.
- Pharma-founded and funded parks, including J&J's JLABS in Shanghai and Astellas' SakuLab in Tsukuba, select cohorts of startups as potential future partners, licensees or investments.
- Government and institution-linked incubators such as HKSTP in Hong Kong, BioBAY in Suzhou and C-CAMP in Bengaluru offer subsidized, time-limited space to support cluster development.
Beyond renting lab space, life sciences organizations can also outsource development and manufacturing to CDMOs, or research to CROs, which as a result reduces the lab space they need to manage.
As more lab space is delivered through operators, incubators and contract organizations, robust and technically equipped FM becomes as critical a capability for these operators as for the organizations occupying their space.
Equipped: a smaller footprint with a bigger specification
Automation and AI are changing how experiments are run inside R&D labs. A report by McKinsey & Company estimates that comprehensive R&D automation could bring products to market more than 500 days faster, while lab automation levers could lower R&D development costs by 25%.
Investment in this area is moving beyond pilot programs. In Tokyo, ten robots are already running a biology lab at the Institute of Science Tokyo's Robotics Innovation Center, and researchers aim to scale to thousands of robots by 2040. In January 2026, Eli Lilly and Nvidia announced up to US$1 billion, five-year co-investment in robotics and AI for new drug discovery. Novo Nordisk has also purchased an autonomous laboratory from Ginkgo Bioworks to run at its new research facility in Massachusetts.
JLL's 2026 Life Sciences Real Estate Trends to Watch found that AI-first biotechnology firms use 15-20% less R&D lab space than traditional biotechnology firms. However, the space they retain carries higher infrastructure requirements. Robotic systems need floors reinforced beyond standard bench loads, continuous high-density power backed by uninterruptible power supply (UPS), and cooling capable of managing concentrated heat loads.
For CRE teams, building specifications to run lab space increasingly need to support robotics and compute alongside conventional bench space.
Powered: sustainability designed in from day one
Labs are resource-intensive by design. Industry benchmarks suggest they consume two to three times the energy of a typical office and four to five times the water of commercial buildings of similar size. Many R&D labs operate around the clock with controlled temperature and humidity, and typically require 6-12 air changes per hour, compared with 4-6 air changes per hour for standard office space.
Alongside these resource demands, sustainability expectations are rising. Globally, 97 life sciences companies have validated their net-zero target with the Science Based Targets initiative (SBTi), around a third of which are in Asia. These commitments are increasingly reflected at the facility level. My Green Lab, a non-profit organization, certifies laboratories on sustainability practices such as energy, water and waste management, and more than 4,500 labs worldwide now hold its certification, up from only 17 in 2016.
For FM teams, the most effective starting point is where energy use concentrates. According to My Green Lab, HVAC accounts for around 60% of a typical lab's energy use, followed by plug load at 22%.
Many of the most effective measures rely on operational discipline rather than capital investment. Retro-commissioning existing HVAC systems, setting airflow by measured risk with environmental health and safety (EHS) sign-off, managing cold storage as an energy asset and powering down idle equipment on a schedule can all reduce energy use without compromising lab safety.
Cutting carbon emissions in labs
Success stories
Cutting HVAC cost and carbon in an R&D lab: At a global healthcare company’s lab in Argentina, JLL introduced monthly cleaning of air handlers, switched to longer-lasting metal-framed pre-filters and renegotiated supplier terms. Filter purchases fell by around 30%, saving 35-45% of the 2025 filter budget.
Strategic imperatives for CRE teams managing R&D labs
R&D labs house specialized infrastructure that is critical to scientific progress and competitive advantage. As portfolios expand, CRE teams need to evolve from traditional space planning toward technical space and operations management, with FM capability considered from the earliest planning stages. JLL Research identifies six FM practices that keep R&D labs safe, efficient and ready for automation:
- Let biosafety level set the operating regime: Rather than managing a building as one unit, FM teams work zone by zone, continuously monitoring pressure cascades and keeping fume hoods and biosafety cabinets on a strict certification cycle.
- Tune HVAC before replacing it: Retro-commissioning and risk-based airflow set-backs should come before capital projects. Air change rates need to be validated to each lab class, as over-ventilating is as costly as under-ventilating, and backup power for HVAC should be tested monthly.
- Clean for containment control: Cleaning protocols, tools and products are calibrated to each zone, with badge-trained staff and cleaning runs scheduled around experiment cycles.
- Track waste as a cost signal: Segregating waste at source and tracking cost by stream helps surface over-ordering and reagent waste.
- Keep food and drink outside the lab: Food handover, storage and break areas sit outside controlled zones, with PPE removal checkpoints in between.
- Link inventory to the work order: A central system tracking expiry and hazardous volumes, connected to the FM work-order platform, enables smart reordering and flags expiring stock before it becomes waste.
Success stories
- Sustaining compliance and cost efficiency across Singapore and Japan: For a leading global pharmaceutical company, JLL manages a greenfield GMP manufacturing, cleanroom and lab facility in Singapore and a 30-year-old high-containment manufacturing site in Japan, including support through multiple health authority audits. The program has saved US$1 million since going live in April 2023, with 2% committed year-on-year savings.
- Scaling one FM model across four markets: A multinational pharmaceutical company brought seven sites across Japan, China, Singapore and India, covering 1.16 million sq ft of GMP plants, labs and offices, under a single JLL Integrated Facilities and Labs Management model. This replaced fragmented site-by-site management and standardized practices across manufacturing and R&D space.
- Minimizing scientist downtime during an R&D consolidation: JLL’s Occupancy Planning and Management team helped a leading U.S. pharmaceutical company vacate a 1.29 million sq ft R&D site, moving, redeploying or disposing of 4,000 pieces of equipment. Scientist downtime was 75% lower than the eight-to-ten-week industry standard.
Three readiness questions can help organizations assess whether their R&D lab strategy is fit for the future:
- Accessed: Can the space scale up, down or out as the science moves through clinical stages?
- Equipped: Does the building specification support robotics and compute, not just desks?
- Powered: Can the lab meet energy and certification expectations from the design stage?

